TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Attendance at mental health appointment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to return to unrestricted full duty
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First variceal bleed
Endpoint domain: Mortality/survival
Primary endpoint: breath-hydrogen excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mean HK value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intrinsic clotting time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clot firmness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Protamine dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean maximum concentration (C(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve for the given dose interval (AUC(tau))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nutrition knowledge score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Serum cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: periprosthetic bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stem stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to complete block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of NAA/Cho and NAA/Cr ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of NAA levels with outcomes at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Follow-up of previously abnormal lipid results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Full lipid profiles requests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Referrals decrease
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Susceptibility to demineralization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: early symptom improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in flexed posture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Karnofsky Performance Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Role-Physical score
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Mean change in Hct
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in SF-36 scale scores (physical functioning)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Adverse events (chest pain, nausea, fatigue)
Endpoint domain: Adverse events/effects
Primary endpoint: Recovery time from sensory blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy non-inferiority
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease of drinking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: %CSA(<5) correlation with Ppa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Need for propofol and alfentanil during anesthesia
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Need for morphine and metamizole after surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pain 18 hours after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Executive function performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean allantoin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Response Rate (RR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Polyp and adenoma detection rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: QALYs increased
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Average total costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: 30-day depression prevalence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Lifetime depression prevalence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Potassium level in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Breastfeeding prevalence at 6-8 weeks
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cost per additional baby breast fed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of patients with a good outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: total body lean tissue mass (LTM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: serum interleukin-6 (IL-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: risk of death or major cardiovascular events
Endpoint domain: Mortality/survival
Primary endpoint: Pain during photodynamic therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medicine compliance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Hemoglobin (Hb) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Global Aesthetic Improvements Scale (GAIS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Visual Analog Scale for pain assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bruising and ecchymosis
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of optimum debulking
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Median disease-free interval
Endpoint domain: Mortality/survival
Primary endpoint: ET duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progesterone and oestradiol levels in FF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: 3βHSD, LHR and INHB‐A gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Clavien-Dindo complication severity grade
Endpoint domain: Adverse events/effects
Primary endpoint: Intraprocedural bleeding frequency
Endpoint domain: Adverse events/effects
Primary endpoint: Achieved PASI 75
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Complete clearance of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in mean PASI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: PC20‐methacholine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: time until expulsion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cure rate at 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean maximum observed serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the zero‐to‐infinity serum concentration‐time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean half‐life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of removed sentinel lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Association of FTND with cotinine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: forearm blood flow to all vasodilators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Combined risk of ischaemic stroke, myocardial infarction or vascular death
Endpoint domain: Mortality/survival
Primary endpoint: Bacterial reduction within the apical groove
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Type 1 closure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventral striatal responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ventilatory drive
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: counselor awareness of client risk behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative blood release of troponin-T
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: early metabolic activity (AUC(GIR) 0‐6 h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: late metabolic activity (AUC(GIR) 12‐28 h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: voice-related outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with goal attainment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of change in cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: health and functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: psychological/spiritual well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Functional profile length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of DV state change after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency rate of nosocomial pneumonia
Endpoint domain: Mortality/survival
Primary endpoint: Fever (rectal temperature > or =38 degrees C)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of upper respiratory tract infections
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of common cold
Endpoint domain: Adverse events/effects
Primary endpoint: AUC(o,t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS‐A score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total airway resistance at 5 Hz
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Peripheral airway resistance as the difference between 5 and 20 Hz
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reactance area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: AISRS total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continuous remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in therapeutic strategy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Overall disease manifestations control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastroenteritis hospitalization rates
Endpoint domain: Mortality/survival
Primary endpoint: stimulant craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-HBs seroprotection rates ≥10mIU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-HPV-16 seroconversion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-HPV-18 seroconversion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Discussions about end-of-life care
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Durable power of attorney completion rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Success rates of local anaesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intelligibility of audio systems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge of SIDS risk factors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Compliance with recommendations about SIDS prevention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Immunoreactive cell counts of SP, NGF, and NT-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: serum hyaluronic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median survival from start of maintenance
Endpoint domain: Mortality/survival
Primary endpoint: Acceptability ratings for e-SBI
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of participants choosing to stop messages
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: fewer migraine days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ratings of hunger
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional outcome prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of overall clinical progression of BPH events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Half-life of melagatran
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal clearance (CL(R)) of melagatran
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of patients free from PONV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of PONV
Endpoint domain: Adverse events/effects
Primary endpoint: Gap-detection thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete remission rate at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintenance of complete remission at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintenance of complete remission at 18 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of HIV-1 infection
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of N gonorrhoeae infection
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of C trachomatis infection
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in UTIs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of persons diagnosed with acute URTI
Endpoint domain: Adverse events/effects
Primary endpoint: Number of URTI events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in percentage of CD3+ cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: stone fragmentation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: total lithotripsy time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Linezolid-related adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: median burden of hypoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median burden of hyperoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median postoperative stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Pain control
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean energy values for carbohydrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: biochemical progression
Endpoint domain: Mortality/survival
Primary endpoint: Hip development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discontinuation or reduction of antidiabetic drugs
Endpoint domain: Adverse events/effects
Primary endpoint: lumbar flexion range of motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total volume of blood expelled per hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Refill time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Venous flow velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: undetectable viral load at week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sympathetic Nerve Activity (SNA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Self-selected walking speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak treadmill speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen consumption rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary RBP as a predictor of CKD progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urinary MCP‐1 as a predictor of CKD progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Good outcome percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LOC eating episode frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of blood lost
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Respiratory distress
Endpoint domain: Adverse events/effects
Primary endpoint: SP and CGRP expression in periodontal ligament
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RF100Hz
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of stool frequency and consistency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mRS improvement from 3 months to 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elevation of plasma ketone concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvements in cognitive function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of CVS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Mean MCA velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: GOS at discharge
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Plasma fluticasone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in medical costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Onset of relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: wound closure time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean increase in left prefrontal white matter (WM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in stroke risk
Endpoint domain: Mortality/survival
Primary endpoint: Arm Muscle Circumference (AMC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fat Mass (FM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean symptom score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Duration of postprandial period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Migrating motor complex cycle length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Increase in relaxation (EEG delta activity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major hemorrhagic events
Endpoint domain: Adverse events/effects
Primary endpoint: postbronchodilator FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Thickness of the dentin wall
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Simple motor speed (Finger Tapping Test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean operative duration
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pain (overall level)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sudden hearing loss
Endpoint domain: Adverse events/effects
Primary endpoint: Time for restoring consciousness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fetal growth retardation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes